Las Vegas, NV -- (SBWIRE) -- 01/08/2014 -- EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.EquityObserver.com issues a special report on the following stocks: Textura Corp (NYSE:TXTR), KB Home (NYSE:KBH), Amarin Corporation plc (ADR) (NASDAQ:AMRN), Myriad Genetics, Inc (NASDAQ:MYGN)
Textura Corp (NYSE:TXTR) opened the session at $32.72, trading in a range of $27.85 - $32.75, and closed at $28.67. The stock showed a negative performance of -10.41% in the last trading session. The stock traded on a volume of 3.03 million shares and the average volume of the stock remained 797,147.00 shares. Textura Corporation is a provider of on-demand business collaboration software to the commercial construction industry. The Company’s solutions are focused on facilitating collaboration between owners/developers, general contractors and subcontractors. The Company offers PlanSwift, a take-off and estimating solution used in preparing construction bids, and Contractor Default Claims Management, which supports the process of documenting a subcontractor default insurance claim.
Will TXTR Get Buyers Even After The Recent Rally? Find Out Here
KB Home (NYSE:KBH) traded 2.95 million shares in the last business day while the average volume of the stock remained 3.70 million shares. The 52 week range of the stock remained $15.48 - $251.4. The stock showed a negative movement of -2.10% to end at $17.69. KB Home is a builder of single-family residential homes, townhomes and condominiums. It constructs and sells homes homes through its operating divisions under the name KB Home. It operates homebuilding and financial services business serving homebuyers in various markets across the United States. Its homebuilding operations offer a variety of new homes designed primarily for first-time, move-up and active adult homebuyers, including attached and detached single-family residential homes, townhomes and condominiums.
Has KBH Found The Bottom And Ready To Gain Momentum? Find Out Here
Amarin Corporation plc (ADR) (NASDAQ:AMRN) reported 2.95 million shares were exchanged during the last trade, while the average volume is about 5.19 million shares. The stock dropped -0.99% and finished the day at $2.00. Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Company’s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA).
Why Should Investors Buy AMRN After the Recent Fall? Just Go Here and Find Out
Myriad Genetics, Inc (NASDAQ:MYGN) the stock advanced 0.10% and finished the session at $21.05. Traded with volume of 2.93 million shares in the prior session and the average volume of the stock remained 2.64 million shares. Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis.
Will MYGN Continue To Move Higher? Find Out Here
About Equity Observer
Equity Observer delivers intra-day insights into the equities, tech and investment world. The website is a window into what’s going on in the business world and why.
EquityObserver.com covers the breadth of the markets, from stocks and bonds to ETFs, options, emerging markets, activities at the Fed and more.
The disclaimer is to be read and fully understood before using our site, or joining our email list.
http://www.equityobserver.com/ has a no tolerance spam policy; we will not sell or re-distribute your email to any 3rd party. A If applicable, please also unsubscribe from the newsletter using the link at the bottom of the email if you no longer wish to receive our emails. We only send our newsletters to opt-in members.
PLEASE NOTE WELL: The http://www.equityobserver.com/ employees and contributors are NOT registered as an Investment Adviser in any jurisdiction whatsoever.
Read Full Disclaimerat: http://www.equityobserver.com/disclaimer-2/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)